Table 1_Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lym

A retrospective analysis of 195 adult patients with relapsed/refractory large B-cell lymphoma who underwent Next-Generation Sequencing. The dataset, authored by Rui Liu and last updated in June 2026, compares survival outcomes for patients with and without TP53 mutations treated with either CAR-T cell therapy or chemotherapy-based approaches.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between TP53-mutated and wild-type patient groups.
• Analyze the differential impact of CAR-T therapy versus chemotherapy on objective response rates in TP53-mutated cohorts.
• Investigate the association between specific TP53 mutation types (e.g., missense vs. disruptive, DBD vs. non-DBD) and patient outcomes.
• Assess the incidence and severity of CAR-T-related toxicities (e.g., cytokine release syndrome) relative to mutation status.

Strengths

• Includes 195 patient records with 75 identified TP53 mutations, providing a defined cohort for analysis.
• Stratifies patients into four groups based on TP53 mutation status and treatment modality (CAR-T vs. chemotherapy).
• Reports specific survival metrics, including median OS of 12.13 months for TP53-mutated patients on CAR-T therapy versus 2.20 months on chemotherapy.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or institutional bias inherent to a single retrospective study.

Provenance

Source

Rui Liu via figshare

Collection Method

Retrospective analysis of patient records and Next-Generation Sequencing (NGS) data.

Freshness

Last updated 2026-06-03 06:06:58; freshness should be verified.